News
Novartis takes $1.9bn hit from Avidity takeover in Q3
Novartis's third-quarter results included a $1.9bn impairment relating to its $12bn takeover of Avidity, though CEO insists it remains a good deal.
News
Judge backs Lilly in Novo lawsuit over weight-loss drug ads
A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.
News
Bayer gets first approval for stroke drug asundexian
Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.
Sales & Marketing
Ending rational disengagement: Bridging the strategy-reality...
Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.
News
AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN
AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
